Adrenal failure in patients with breast carcinoma after long-term treatment of cyclic alternating oestrogen progesterone.
作者信息
Hug V, Kau S, Hortobagyi G N, Jones L
机构信息
Department of Medical Oncology (Breast Medical Oncology), and Gynecology, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
出版信息
Br J Cancer. 1991 Mar;63(3):454-6. doi: 10.1038/bjc.1991.105.
Abstract
摘要
相似文献
1
Adrenal failure in patients with breast carcinoma after long-term treatment of cyclic alternating oestrogen progesterone.长期接受周期性交替雌激素和孕激素治疗的乳腺癌患者出现肾上腺功能衰竭。
Br J Cancer. 1991 Mar;63(3):454-6. doi: 10.1038/bjc.1991.105.
2
Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients.大剂量醋酸甲羟孕酮对乳腺癌患者肾上腺抑制的机制。
Cancer Chemother Pharmacol. 1985;15(2):167-70. doi: 10.1007/BF00257530.
3
Oral high-dose medroxyprogesterone acetate causes adrenal suppression in patients with breast cancer.口服高剂量醋酸甲羟孕酮会导致乳腺癌患者出现肾上腺抑制。
Eur J Cancer Clin Oncol. 1982 Oct;18(10):1035-6. doi: 10.1016/0277-5379(82)90253-x.
4
Cushing syndrome and medroxyprogesterone acetate.
Lancet. 1990 May 5;335(8697):1094. doi: 10.1016/0140-6736(90)92663-3.
5
Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
Southeast Asian J Trop Med Public Health. 1985 Dec;16(4):634-7.
6
Pharmacoclinical data on high dose medroxyprogesterone acetate in advanced breast cancer.醋酸甲羟孕酮高剂量用于晚期乳腺癌的药物临床数据。
Breast Cancer Res Treat. 1986;8(2):161-3. doi: 10.1007/BF01807705.
7
[Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
Gan To Kagaku Ryoho. 1989 Nov;16(11):3555-8.
8
9
10
Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Chemioterapia. 1987 Dec;6(6):396-8.
引用本文的文献
1
Cushing's syndrome with adrenal suppression and masked hyperandrogenism by high-dose medroxyprogesterone acetate for treatment of endometrial cancer in a young woman with polycystic ovarian syndrome.在一名患有多囊卵巢综合征的年轻女性中，因使用大剂量醋酸甲羟孕酮治疗子宫内膜癌而出现肾上腺抑制和隐匿性高雄激素血症的库欣综合征。
Endocrine. 2015 Nov;50(2):519-21. doi: 10.1007/s12020-015-0722-7. Epub 2015 Aug 23.
本文引用的文献
1
[Estrogen-induced proteins secreted by MCF7 human breast cancer cells stimulate their proliferation].[雌激素诱导人MCF7乳腺癌细胞分泌的蛋白质刺激其增殖]
C R Seances Acad Sci III. 1983 Jan 24;296(3):151-6.
2
Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate.大剂量醋酸甲羟孕酮治疗转移性乳腺癌的药代动力学和药效学基础。
Cancer. 1984 Sep 15;54(6 Suppl):1208-15. doi: 10.1002/1097-0142(19840915)54:1+<1208::aid-cncr2820541319>3.0.co;2-k.
3
4
Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients.大剂量醋酸甲羟孕酮对乳腺癌患者肾上腺抑制的机制。
Cancer Chemother Pharmacol. 1985;15(2):167-70. doi: 10.1007/BF00257530.
5
Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Chemioterapia. 1987 Dec;6(6):396-8.
6
The Cushing syndrome induced by medroxyprogesterone acetate.醋酸甲羟孕酮所致库欣综合征
Ann Intern Med. 1989 Nov 1;111(9):758-60. doi: 10.7326/0003-4819-111-9-758.
7
Sequential cyclic combined hormonal therapy for metastatic breast cancer.转移性乳腺癌的序贯周期性联合激素治疗
Cancer. 1989 Sep 1;64(5):1002-6. doi: 10.1002/1097-0142(19890901)64:5<1002::aid-cncr2820640505>3.0.co;2-b.
8
Adrenal steroids as parameters of the bioavailability of MA and MPA.肾上腺类固醇作为美金刚和1-甲基-4-苯基吡啶离子生物利用度的参数。
Eur J Cancer. 1990 Mar;26(3):359-62. doi: 10.1016/0277-5379(90)90234-k.
9
Cushing syndrome and medroxyprogesterone acetate.
Lancet. 1990 May 5;335(8697):1094. doi: 10.1016/0140-6736(90)92663-3.
Zotero 插件